ag-Ip-news

The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization
Arabic
Advanced Search
zzzzzzzzzzzzzzzzz
Mailing List Sign Up
Enter your e-mail address to receive daily headlines.

Unsubscribe
Click here for World Law news from NewsNow.co.uk
WAP Service


AGIPNEWS6671

10/1/2009 11:17 GMT
ag-IP-news
Silence Therapeutics Granted New Patent

LONDON - Silence Therapeutics plc, the leading European biopharmaceutical company focused on RNA interference, announced that the European Patent Office (EPO) has granted a patent to Silence that covers the company‘s lead product candidate, Atu027, a press release by the company stated.

On January 7, 2009, the EPO issued EP 1 536 827 B1, “Use Of Protein Kinase N Beta,” which covers use of the protein Kinase N3 (PKN3) gene for drug-screening, diagnostic and therapeutic purposes.

PKN3 is the target for Silence’s lead compound Atu027, which is being developed for the treatment of advanced solid cancers and which is scheduled to enter clinical trials in 2009.

The patent issued to Silence includes claims that cover any small interfering RNA molecule or antisense oligonucleotide used for the treatment of a wide range of cancers.

“This European patent further strengthens Silence’s IP position, and follows November’s grant of the core US patent by the US Patent and Trademark Office,” General Counsel and Vice President, Intellectual Property John Lucas stated.

“This latest patent gives Silence an exclusive position not only with Atu027, but also with any siRNA or antisense molecule used to target PKN3 for the treatment of cancer and other diseases,” he added.

“Silence has made a great start to 2009. Even before our lead compound Atu027 enters the clinic, we have secured our Intellectual Property with an issued patent,” Silence Therapeutics Chairman and CEO Iain Ross said.

“We now have patent protection for Atu027 in the two largest pharmaceutical markets – the US and Europe. Our partners and investors can be confident that Silence can protect its technology and products,” he concluded.


Related Articles
Another Patent in Graham Family Allowed in US
TASER International Wins Judgment and Final Injunction in Patent Infringement Against Stinger Systems
X-Rite Receives US Patent
Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent from USPTO
Centrify Corporation Files Patent Litigation Against Quest Software
AdvanSource Biomaterials Announces Patent for Antimicrobial Polyurethane Resins
KEY HIV/AIDS Drug Patents Challenged by PUBPAT
Quest Software Enforces Key Patent Covering Its Quest Authentication Services Product
AdvanSource Biomaterials Announces Patent for Antimicrobial Polyurethane Resins
Datalink Awarded $8 Million Project by Global Consulting

Top
Go

Home | About Us | How to Use Our Services | Links | Download Our News Ticker | FAQ | What is IP? | Contact Us
Copyright © 2008 ag-IP-news All Rights Reserved
Disclaimer   Terms of Use    Privacy Policy